Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes.

Clin Exp Immunol

Laboratorio de Fisiopatología Ovárica, Centro de Estudios Farmacológicos y Botánicos, Universidad de Buenos Aires, Paraquay, Argentina.

Published: August 2008

The aim of the present study was to assess the effect of dehydroepiandrosterone (DHEA: 10 microM) and metformin (10 microM and 100 microM) in regulating proliferation of cultured T lymphocytes. T cells were isolated from lymph nodes of prepuberal BALB/c mice. We found that DHEA, metformin and DHEA + metformin added to the incubation media diminished proliferation of T cells. The inhibition by DHEA was higher than that produced by metformin, while the combined treatment showed a synergistic action that allowed us to speculate distinct regulatory pathways. This was supported later by other findings in which the addition of DHEA to the incubation media did not modify T lymphocyte viability, while treatment with metformin and DHEA + metformin diminished cellular viability and increased both early and late apoptosis. Moreover, DHEA diminished the content of the anti-oxidant molecule glutathione (GSH), whereas M and DHEA + metformin increased GSH levels and diminished lipid peroxidation. We conclude that DHEA and metformin diminish proliferation of T cells through different pathways and that not only the increase, but also the decrease of oxidative stress inhibited proliferation of T cells, i.e. a minimal status of oxidative stress, is necessary to trigger cellular response.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2492903PMC
http://dx.doi.org/10.1111/j.1365-2249.2008.03696.xDOI Listing

Publication Analysis

Top Keywords

dhea metformin
20
proliferation cells
12
dhea
9
metformin
8
metformin dhea
8
incubation media
8
oxidative stress
8
proliferation
5
dehydroepiandrosterone metformin
4
metformin regulate
4

Similar Publications

Introduction: Polycystic ovary syndrome is a common chronic condition characterized by insulin resistance and hyperandrogenism, leading to significant health risks and impaired quality of life. Sodium-glucose transporter type 2 inhibitors have shown promise in improving the metabolic profile of women with polycystic ovary syndrome. However, their impact on hormonal parameters and cycle disorders remains uncertain.

View Article and Find Full Text PDF

Background: Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder accompanied by ovulatory dysfunction. Insulin resistance (IR) is a key pathogenic mechanism in PCOS, and insulin sensitizers, such as metformin and pioglitazone, can improve PCOS symptoms. Chiglitazar, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, is also an insulin sensitizer; however, its therapeutic effects have not yet been studied in PCOS.

View Article and Find Full Text PDF

Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study.

Front Endocrinol (Lausanne)

October 2024

Department of Histology and Embryology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.

Article Synopsis
  • Polycystic ovary syndrome (PCOS) is a common condition among reproductive-age women, with few effective treatment options; research suggests fertility nutrient supplements might help, but their influence on PCOS risk is unclear.
  • This study used Mendelian Randomization to analyze 10 specific fertility nutrients, including omega-3 fatty acids and curcumin, to determine their causal effect on PCOS risk.
  • Results showed that omega-3 fatty acids can reduce PCOS risk while betaine increases it; certain nutrients like berberine and curcumin also demonstrated potential protective roles against PCOS.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether a WeChat-based digital intervention is effective in managing polycystic ovary syndrome (PCOS) compared to metformin treatment in women with insulin resistance.
  • Eighty women were randomly assigned to either the digital intervention group or the metformin group, and outcomes such as insulin resistance, menstruation frequency, and body weight were measured over 12 weeks.
  • Results showed both treatments improved menstruation frequency and body weight significantly, but the digital intervention did not provide a statistically significant advantage over metformin in reducing insulin resistance.
View Article and Find Full Text PDF

Background: Metformin plays a major part in the treatment of polycystic ovarian syndrome .Trials are being conducted to compare the effectiveness of combination of metformin with cabergoline in the treatment of hyperprolactinemia and polycystic ovarian syndrome.

Objectives: The purpose of this study is to compare the effectiveness of metformin monotherapy and combination therapy with cabergoline versus metformin for the management of polycystic ovarian syndrome with hyperprolactinemia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!